Pigs vaccinated with Fostera®PCV MH equally protected, weighed nearly 8 pounds more in large comparison trial
Pigs vaccinated with Fostera® PCV MH were equally protected against porcine circovirus (PCV) type 2d as well as Mycoplasma hyopneumoniae (M. hyo) and weighed 7.78 pounds more than pigs vaccinated with Circumvent® PCV-M G21 in a trial involving 550 pigs.2
“Pigs that received two doses of Fostera PCV MH had signiﬁcantly better average ﬁnal weight — 257.78 pounds — and average daily gain (ADG) compared to the Circumvent group,” said Lucina Galina, DVM, PhD, director of swine technical services, Zoetis (Figure 1). They also weighed nearly 16 pounds more than unvaccinated controls, again a signiﬁcant diﬀerence.
The next best ﬁnal average weight and ADG were among pigs in the one-dose Fostera PCV MH group. These results were numerically better than results in the Circumvent PCV-M G2 group and a third group vaccinated with CircoFLEX® and MycoFLEX®.3
For the study, commercial pigs were raised in a commercial-like environment. The pigs had two prevalent inﬂuenza subtypes (H1N2, H3N2) and Streptococcus suis, not an uncommon ﬁeld scenario, Galina said of the Zoetis-sponsored study, conducted at a Midwest contract research facility.
Investigators distributed pigs from multiple litters into groups of 110. Pigs from each litter were represented in every group, which received one of ﬁve treatments per label directions:
- 1-ml dose of Fostera PCV MH at 3 and 5 weeks of age
- 2-ml dose of Fostera PCV MH at 3 weeks of age
- 1-ml dose of Circumvent PCV-M G2 at 3 days of age and 3 weeks later
- 1-ml dose of Ingelvac CircoFLEX plus 1-ml dose of Ingelvac MycoFLEX at 3 weeks of age
- 1-ml dose of saline at 3 and 5 weeks of age (control group)
At 8 weeks of age, researchers challenged pigs with M. hyo and, 1 week later, with a high, intranasal and intramuscular dose of PCV2d, the most predominant PCV genotype based on sequencing of samples submitted to Iowa State’s Veterinary Diagnostic Laboratory.4 Investigators tracking results did not know which treatment each group received.
All three vaccines controlled PCV viremia well, based on cycle-threshold values, compared to unvaccinated, challenged controls. “This clearly demonstrated that one- or two-dose regimens of Fostera PCV MH are as eﬀective as its competitors,” she said.
Injection-site reactions were negligible, Galina added, and there were no signiﬁcant diﬀerences among vaccine groups based on immunohistochemistry, an indicator of virus in lymph nodes.
Fewer gross lesions
At 12 weeks of age, investigators examined 24 pigs from each group for gross lung lesions. Pigs in both Fostera PCV MH groups and the Circumvent PCV-M G2 group had signiﬁcantly (p<0.05) lower lesion scores than the CircoFLEX plus MycoFLEX group.
Galina noted that Zoetis recently increased the PCV-antigen level in Fostera PCV MH and that the MetaStim® adjuvant in Fostera PCV MH helps pigs mount a strong, cell-mediated immune response.5
“These recent study results demonstrate that Fostera PCV MH can provide pork producers with an eﬀective and safe option for managing PCV in their herds,” she said.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
1 Circumvent PCV-M G2 is a Merck Animal Health product.
2 Data on File, Study Report No. 16PRGBIO-01-01, Zoetis LLC.
3 Ingelvac CircoFleX and ingelvac mycoFleX are Boehringer Ingelheim products.
4 Xiao C-T, et al. PCV2d-2 is the predominant type of PCV2 CNa in pig samples collected in the us during 2014-2016. Vet Microbiol. 2016 dec;197:72-77.
5 Seo HW, et al. comparative analyses of humoral and cell-mediated immune responses upon vaccination with different commercially available single-dose porcine circovirus type 2 vaccines. Res Vet Sci. 2014;97:38-42.
DISCOVERIES, Issue 1
Discoveries is a series of research news reports written by the editors of Pig Health Today on behalf of the US Pork Business of Zoetis.
Posted on March 21, 2018